文献速递冠心病血脂与心血管预防

APOB或PCSK9罕见蛋白截短变异与低密度脂蛋白胆固醇水平及冠心病风险的关联

Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease.
PubMed 文献 · JAMA Cardiol · 2023-01-01

本研究纳入5项NHLBI研究和UK Biobank共209 537人,分析APOB或PCSK9蛋白截短变异(PTV)与LDL-C及冠心病风险的关系。携带者LDL-C较低,冠心病风险降低49%(HR 0.51),支持降低LDL-C对冠心病预防的因果作用。

要点

  • APOB或PCSK9 PTV携带者LDL-C水平显著降低。
  • 携带者冠心病风险降低约49%,在两个队列中一致。
  • 结果支持LDL-C为冠心病因果危险因素。

核心结论

  • APOB或PCSK9 PTV与较低LDL-C暴露及约49%的冠心病风险降低相关。

研究设计与样本

  • 研究纳入5项NHLBI研究(1971-2002年招募,5-84岁,全基因组测序)和UK Biobank(2006-2010年招募,40-69岁,全外显子测序)的参与者。
  • NHLBI研究共19 073人,UK Biobank共190 464人,总样本209 537人。

主要发现

  • NHLBI研究中139人(0.7%)携带APOB或PCSK9 PTV,其估计未治疗LDL-C低49 mg/dL(95%CI 43-56)。
  • UK Biobank中662人(0.4%)携带PTV,估计未治疗LDL-C低45 mg/dL(95%CI 42-47)。

临床怎么用

  • APOB或PCSK9 PTV携带状态与较低的LDL-C和冠心病风险相关,支持通过降低LDL-C来预防冠心病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Protein-truncating variants (PTVs) in apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with significantly lower low-density lipoprotein (LDL) cholesterol concentrations. The association of these PTVs with coronary heart disease (CHD) warrants further characterization in large, multiracial prospective cohort studies. OBJECTIVE: To evaluate the association of PTVs in APOB and PCSK9 with LDL cholesterol concentrations and CHD risk. DESIGN, SETTING, AND PARTICIPANTS: This studied included participants from 5 National Heart, Lung, and Blood Institute (NHLBI) studies and the UK Biobank. NHLBI study participants aged 5 to 84 years were recruited between 1971 and 2002 across the US and underwent whole-genome sequencing. UK Biobank participants aged 40 to 69 years were recruited between 2006 and 2010 in the UK and underwent whole-exome sequencing. Data were analyzed from June 2021 to October 2022. EXPOSURES: PTVs in APOB and PCSK9. MAIN OUTCOMES AND MEASURES: Estimated untreated LDL cholesterol levels and CHD. RESULTS: Among 19 073 NHLBI participants (10 598 [55.6%] female; mean [SD] age, 52 [17] years), 139 (0.7%) carried an APOB or PCSK9 PTV, which was associated with 49 mg/dL (95% CI, 43-56) lower estimated untreated LDL cholesterol level. Over a median (IQR) follow-up of 21.5 (13.9-29.4) years, incident CHD was observed in 12 of 139 carriers (8.6%) vs 3029 of 18 934 noncarriers (16.0%), corresponding to an adjusted hazard ratio of 0.51 (95% CI, 0.28-0.89; P = .02). Among 190 464 UK Biobank participants (104 831 [55.0%] female; mean [SD] age, 57 [8] years), 662 (0.4%) carried a PTV, which was associated with 45 mg/dL (95% CI, 42-47) lower estimated untreated LDL cholesterol level. Estimated CHD risk by age 75 years was 3.7% (95% CI, 2.0-5.3) in carriers vs 7.0% (95% CI, 6.9-7.2) in noncarriers, corresponding to an adjusted hazard ratio of 0.51 (95% CI, 0.32-0.81; P = .004). CONCLUSIONS AND RELEVANCE: Among 209 537 individuals in this study, 0.4% carried an APOB or PCSK9 PTV that was associated with less exposure to LDL cholesterol and a 49% lower risk of CHD.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Dron JS, Patel AP, Zhang Y, et al. Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease. JAMA Cardiol. 2023. PMID: 36723951. doi:10.1001/jamacardio.2022.5271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。